Avalo Therapeutics, Inc. (NASDAQ:AVTX – Get Free Report) saw a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 54,200 shares, a decline of 8.9% from the September 15th total of 59,500 shares. Approximately 0.6% of the shares of the company are short sold. Based on an average trading volume of 17,700 shares, the days-to-cover ratio is currently 3.1 days.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the stock. Affinity Asset Advisors LLC purchased a new stake in shares of Avalo Therapeutics in the first quarter valued at approximately $218,000. Ikarian Capital LLC purchased a new stake in shares of Avalo Therapeutics in the first quarter valued at approximately $1,015,000. Finally, Logos Global Management LP purchased a new stake in shares of Avalo Therapeutics in the second quarter valued at approximately $6,722,000. 87.06% of the stock is owned by institutional investors and hedge funds.
Avalo Therapeutics Price Performance
Shares of NASDAQ:AVTX opened at $9.29 on Tuesday. Avalo Therapeutics has a 12-month low of $3.95 and a 12-month high of $42.34. The business has a 50 day moving average of $9.22 and a two-hundred day moving average of $11.52.
Avalo Therapeutics Company Profile
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Recommended Stories
- Five stocks we like better than Avalo Therapeutics
- What is a Stock Market Index and How Do You Use Them?
- Tesla Stock: Finding the Bottom or Moving On?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Stanley Druckenmiller’s Latest Moves: What They Mean for You
- Quiet Period Expirations Explained
- 2 Outerwear Stocks to Warm Up Your Portfolio for the Winter
Receive News & Ratings for Avalo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avalo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.